What Happens When You Stop Taking Semaglutide? STEP-4, STEP-1 Extension, and SURMOUNT-4 Tell the Story

Semaglutide isn't like an antibiotic. You don't take a course and stay better. Three large randomized trials — STEP-4, the STEP-1 extension, and SURMOUNT-4 for tirzepatide — have specifically measured what happens to body weight after these drugs are stopped. The numbers are unambiguous: most patients regain about two-thirds of their lost weight within a year of discontinuation. This article walks through the actual published trial data, the proposed biological mechanism, and what these findings should change about how patients and prescribers think about “a course” of GLP-1 therapy.

STEP-4: the dedicated withdrawal trial for semaglutide

The first trial designed specifically to answer the “what happens when you stop” question for semaglutide was STEP-4, published in JAMA in April 2021 by Rubino and colleagues [1]. STEP-4 was a randomized, double-blind, 68-week phase 3a trial with an unusual design: a 20-week run-in period where everyone received semaglutide (16 weeks dose escalation up to 2.4 mg weekly, plus 4 weeks at the maintenance dose), followed by a 48-week randomization where participants who had successfully reached the full 2.4 mg dose were assigned 2:1 to either continue semaglutide or switch to placebo. Both arms continued receiving the same lifestyle intervention (counseling, exercise, calorie tracking) for the entire 68 weeks.

803 participants were randomized at week 20 — 535 to continue semaglutide and 268 to placebo. Every one of them had already lost weight on semaglutide before randomization (mean weight loss during the run-in was 10.6% of starting body weight) [1]. The question was: what happens over the next 48 weeks?

The primary endpoint was percent body weight change from week 20 (the start of randomization) to week 68 (the end of the trial). Here's what STEP-4 actually measured [1]:

Read that carefully. The patients who stayed on semaglutide continued to lose weight — an additional 7.9% over the 48-week randomization phase. The patients who stopped semaglutide regained 6.9 percentage points of body weight over the same window. Combined, the people who continued semaglutide ended the trial about 14.8 percentage points lighter than the people who stopped. That's the largest divergence ever recorded in a weight-loss withdrawal trial.

Translated into proportional terms: STEP-4 placebo participants had lost a mean 10.6% during the run-in, then regained 6.9 points of body weight over the next 48 weeks. That's approximately 65% of the weight they had lost — gone within ~11 months of stopping the drug [1].

STEP-1 extension: what happens over a full year of discontinuation

STEP-4 measured 48 weeks post-randomization. The follow-up question — what happens after a full calendar year off the drug — was answered by a separate analysis of the STEP-1 cohort, published in Diabetes, Obesity and Metabolism in 2022 by Wilding et al. [3].

The STEP-1 extension followed 327 participants from the original STEP-1 trial [2]. In the original trial, semaglutide produced a mean weight loss of 17.3% (SD 9.3%) over 68 weeks of active treatment, versus 2.0% (SD 6.1%) on placebo [2]. After the active treatment phase ended at week 68, semaglutide was discontinued — the extension simply tracked what happened next.

By week 120 (one full year after the last semaglutide dose), participants who had been on semaglutide had regained 11.6 percentage points of weight. Their net retention from baseline had dropped from 17.3% loss to just 5.6% loss [3]. That's approximately 67% of the weight loss reversed within one year of discontinuation.

Important note for anyone seeing the “two-thirds regain” figure cited in the lay press: it comes from the STEP-1 extension [3], NOT from STEP-4 [1] as it's often misattributed. The two trials measured different things. STEP-4 measured a 48-week withdrawal divergence; the STEP-1 extension measured the full 52-week post-discontinuation trajectory. Both arrive at roughly the same answer (~64–67% regain), but the citation matters.

SURMOUNT-4: the same story for tirzepatide

Tirzepatide (the dual GIP/GLP-1 agonist sold as Zepbound for weight loss and Mounjaro for type 2 diabetes) is a meaningfully more effective drug than semaglutide on the primary efficacy endpoint, but the withdrawal pattern looks essentially the same. SURMOUNT-4, published in JAMA in 2024 by Aronne and colleagues [4], randomized 694 participants who had achieved at least 10% weight reduction during a 36-week tirzepatide lead-in. They were randomized 2:1 to continue tirzepatide or switch to placebo for another 52 weeks.

SURMOUNT-4 also reported that 82.5% of the placebo-switched arm regained at least 25% of the weight they had lost during the initial 36-week treatment phase [4]. That's a stronger regain signal than STEP-4 produced for semaglutide, possibly because tirzepatide's deeper appetite suppression creates a larger gap between the on-drug and off-drug homeostatic set point.

Why the regain happens: the mechanism

GLP-1 receptor agonists work centrally in the hypothalamus. They activate satiety-promoting neurons (particularly POMC and CART neurons in the dorsomedial hypothalamus) and suppress appetite-stimulating NPY/AgRP neurons. The result is a sustained downward shift in the body's appetite set point — patients feel full faster, stop thinking about food between meals, and spontaneously eat less without willpower mediation.

When the drug is withdrawn, two things happen at once:

1. The central appetite suppression disappears within days, because semaglutide's half-life is roughly one week. Hunger and food preoccupation return rapidly.
2. The body's compensatory hormonal signals — ghrelin (the appetite-stimulating gut hormone) and leptin (the satiety hormone secreted by fat tissue) — recalibrate to defend the higher pre-treatment body weight. Ghrelin rises, leptin sensitivity drops as fat stores rebuild, and the homeostatic system actively pulls weight back toward the original set point.

The clinical implication is uncomfortable but unambiguous: for most patients, GLP-1 weight loss is not a cure — it's a disease management strategy that requires ongoing therapy to maintain the benefit. This is exactly why the FDA-approved Wegovy indication explicitly states the drug is for weight reduction and weight maintenance, with the implication that maintenance therapy is expected to be long-term.

What this means if you're considering stopping

If you're currently on semaglutide or tirzepatide and thinking about stopping — for cost reasons, side effects, or because you've hit your target weight — the trial data is clear about what to expect. Most patients in randomized trials regained the majority of their weight within 12 months of discontinuation, even with continued lifestyle intervention.

That doesn't mean stopping is wrong. It means three things:

1. Plan for the long term. If you're budgeting for compounded GLP-1 therapy, budget for years, not months. Our savings calculator shows the real out-of-pocket cost over a multi-year window.
2. Tapering is poorly studied. The trials measured abrupt discontinuation, not gradual dose reduction. There is some clinical experience suggesting that stretching dosing intervals (e.g., moving from weekly to every 10-14 days) can help maintain weight loss at lower drug exposure, but the rigorous trial data isn't there yet.
3. Cost matters more than usual. Because long-term therapy is the expectation, the per-month price gap between providers compounds dramatically over time. Our pricing index and 16-month price movement investigation show how the market has been moving — and how to find the cheapest legitimate provider available in your state.

The bottom line

Three peer-reviewed randomized trials have specifically measured what happens after GLP-1 weight loss medications are stopped. STEP-4 [1], the STEP-1 extension [3], and SURMOUNT-4 [4] all produce the same answer: patients regain the majority of lost weight within a year of discontinuation, even with continued lifestyle intervention. The mechanism is well-described in the published literature — central appetite suppression reverses within days, and hormonal compensation recalibrates body weight toward the pre-treatment set point.

That doesn't mean these drugs don't work. It means they work in the way you'd expect any chronic disease management medication to work — when you take them, the disease (in this case, the body's defended high weight) is suppressed; when you stop, the disease returns. Patients and prescribers should plan accordingly.